Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAB LMB 96 for Mature B-Cell Lymphoma/Leukemia
NCT00002757Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Jun 2001
- Primary completion
- Oct 2003
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, doxorubicin, vincristine, methotrexate, cytarabine and 2 more in non-Hodgkin lymphoma (NHL), B-cell leukemia (BCL), Burkitt lymphoma (BL) and 1 more (7 arms), sponsored by Children's Oncology Group. Primary endpoint: Event Free Survival. Started Jun 2001; status: completed.
02
Drugs
cyclophosphamidedoxorubicinvincristinemethotrexatecytarabine
03
Conditions
non-Hodgkin lymphoma (NHL)B-cell leukemia (BCL)Burkitt lymphoma (BL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00002757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002757.